Summary & Overview
HCPCS G2112: Glucocorticoid Use or Worsening RA Activity
HCPCS Level II code G2112 captures a clinical situation involving low-dose glucocorticoid therapy or changes in rheumatoid arthritis (RA) disease activity. Specifically, the code applies when a patient is on ≤5 mg daily prednisone (or equivalent), when RA activity is worsening, or when glucocorticoid use has been for less than six months. This code is clinically relevant for outpatient rheumatology and other ambulatory settings where medication regimens and disease activity are monitored.
Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how G2112 is used in clinical documentation, the typical service context (medication management and disease activity assessment), and what to expect from payer recognition of the code. The publication also outlines benchmarks and policy considerations relevant to billing and coding for glucocorticoid-related RA assessments, and highlights areas where additional documentation may be needed to support use of the code.
This summary is intended for a national audience of clinicians, coders, and billing professionals seeking concise guidance on the clinical meaning and billing context of HCPCS Level II code G2112.
Billing Code Overview
HCPCS Level II code G2112 describes a clinical status related to glucocorticoid use and rheumatoid arthritis (RA) disease activity. The code applies when a patient is receiving ≤5 mg daily prednisone (or equivalent), or when RA activity is worsening, or when glucocorticoid use is for less than 6 months.
Service type: Medication management / disease activity assessment related to glucocorticoid use in RA.
Typical site of service: Outpatient clinic or ambulatory care setting, including rheumatology offices and other outpatient specialty clinics where glucocorticoid dosing and RA activity are evaluated.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with a history of rheumatoid arthritis presents to a rheumatology clinic for follow-up. The patient is currently taking prednisone at a stable dose of 5 mg daily and reports an increase in joint stiffness and morning swelling over the past 4 weeks. The clinician documents assessment of disease activity, reviews current glucocorticoid dose and duration, and considers adjustments to disease-modifying antirheumatic drug therapy rather than escalation of glucocorticoids. The encounter includes medication reconciliation, joint exam, patient education about steroid risks, and coordination of a short-interval follow-up or laboratory monitoring if therapy changes.
Typical site of service: outpatient rheumatology clinic or ambulatory infusion/administration center for related visits.
Typical patient scenario: adult with established rheumatoid arthritis on low-dose prednisone (≤5 mg daily) presenting with worsening RA activity or a plan to limit glucocorticoid exposure because use has been <6 months.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to manage worsening disease or complex medication management substantially exceeds usual service time documented. |